Current state and future prospects of pharmacological interventions for autism

Neuropsychiatry

Volumn 3, Issue 2, 2013, Pages 245-259

  Vahabzadeh, Arshya ^a   Buxton, David ^b   McDougle, Christopher J ^b,c   Stigler, Kimberly A ^d,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INDIANA UNIVERSITY   (United States)

^e RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYCLOSERINE; DESIPRAMINE; DONEPEZIL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MEMANTINE; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ABDOMINAL PAIN; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; ANXIETY DISORDER; APPETITE; ATAXIA; AUTISM; BEHAVIOR DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPULSION; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; DYSTONIC DISORDER; ECHOLALIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; LIVER TOXICITY; LOW DRUG DOSE; MOOD DISORDER; NAUSEA; OCCUPATIONAL THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; POSTTRAUMATIC STRESS DISORDER; PRESYNCOPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHINOPHARYNGITIS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOCIAL ADAPTATION; SOMNOLENCE; SPEECH THERAPY; STEREOTYPY; TACHYCARDIA; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84876110481     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.13.22     Document Type: Review

References (97)

1. American Psychiatric Association. Task Force on DSM-IV. In: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (4th Edition). American Psychiatric Association, DC, USA (2000).
2. Scahill L, Koenig K, Carroll DH, Pachler M. Risperidone approved for the treatment of serious behavioral problems in children with autism. J. Child Adolesc. Psychiatr Nurs. 20(3), 188-190 (2007).
3. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6), 1533-1540 (2009).
4. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121(3), e441-e448 (2008).
5. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J. Autism Dev. Disord. 39(9), 1339-1349 (2009).
6. Aman MG, Burrow WH, Wolford PL. The Aberrant Behavior Checklist -Community: factor validity and effect of subject variables for adults in group homes. Am. J. Ment. Retard. 100(3), 283-292 (1995).
7. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (3rd Edition). Cambridge University Press, Cambridge, UK (2008).
8. Posey DJ, Stigler K A, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J. Clin. Invest. 118(1), 6-14 (2008).
9. Mccracken JT, Mcgough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347(5), 314-321 (2002).
10. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5), e634-e641 (2004).
11. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 162(6), 1142-1148 (2005).
12. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 55(7), 633-641 (1998).
13. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J. Child Adolesc. Psychopharmacol. 15(6), 869-884 (2005).
14. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J. Am. Acad. Child Adolesc. Psychiatry 48(11), 1110-1119 (2009).
15. Stigler K A, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 14(3), 455-463 (2004).
16. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J. Child Adolesc. Psychopharmacol. 19(3), 265-274 (2009).
17. Marcus RN, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J. Child Adolesc. Psychopharmacol. 21(3), 229-236 (2011).
18. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J. Clin. Psychiatry 72(9), 1270-1276 (2011).
19. Jordan I, Robertson D, Catani M, Craig M, Murphy D. Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder. Psychopharmacology 223(3), 357-360 (2012).
20. Stigler K A, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J. Child Adolesc. Psychopharmacol. 20(1), 75-78 (2010).
21. Stigler K A, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology 223(2), 237-245 (2012).
22. Findling RL, Mcnamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J. Child Adolesc. Psychopharmacol. 14(2), 287-294 (2004).
23. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin. Neuropharmacol. 34(6), 216-219 (2011).
24. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J. Autism Dev. Disord. 35(3), 387-391 (2005).
25. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J. Child Adolesc. Psychopharmacol. 16(5), 541-548 (2006).
26. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med. Princ. Pract. 17(5), 415-418 (2008).
27. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J. Clin. Psychopharmacol. 19(1), 37-44 (1999).
28. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J. Clin. Psychiatry 65(1), 110-113 (2004).
29. Malone RP, Delaney MA, Hyman SB, Cater Jr. Ziprasidone in adolescents with autism: an open-label pilot study. J. Child Adolesc. Psychopharmacol. 17(6), 779-790 (2007).
30. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J. Am. Acad. Child Adolesc. Psychiatry 41(8), 921-927 (2002).
31. Beherec L, Lambrey S, Quilici G, Rosier A, Falissard B, Guillin O. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J. Clin. Psychopharmacol. 31(3), 341-344 (2011).
32. Tuchman R, Cuccaro M. Epilepsy and autism: neurodevelopmental perspective. Curr. Neurol. Neurosci. Rep. 11(4), 428-434 (2011).
33. Davit CJ, Hundley RJ, Bacic JD, Hanson EM. A pilot study to improve venipuncture compliance in children and adolescents with autism spectrum disorders. J. Dev. Behav. Pediatr. 32(7), 521-525 (2011).
34. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry 17(4), 640-655 (1978).
35. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J. Clin. Psychopharmacol. 21(4), 440-444 (2001).
36. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry 36(6), 835-843 (1997).
37. Chan AS, Cheung MC, Han YM, et al. Executive function deficits and neural discordance in children with autism spectrum disorders. Clin. Neurophysiol. 120(6), 1107-1115 (2009).
38. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am. J. Psychiatry 158(7), 1058-1066 (2001).
39. Chez MG, Nowinski CV, Buchanan CP. Donepezil use in children with autistic spectrum disorders. Ann. Neurol. 48, 541 (2000).
40. Handen BL, Johnson CR, Mcauliffe-Bellin S, Murray PJ, Hardan AY. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. J. Child Adolesc. Psychopharmacol. 21(1), 43-50 (2011).
41. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J. Child Neurol. 19(3), 165-169 (2004).
42. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J. Child Adolesc. Psychopharmacol. 16(5), 621-629 (2006).
43. Murphy DG, Daly E, Schmitz N, et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am. J. Psychiatry 163(5), 934-936 (2006).
44. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann. Neurol. 45(3), 287-295 (1999).
45. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatr. 58, 315-320 (1961).
46. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch. Gen. Psychiatry 53(11), 993-1000 (1996).
47. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340(2-3), 249-258 (1997).
48. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch. Gen. Psychiatry 50(6), 441-447 (1993).
49. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J. Child Adolesc. Psychopharmacol. 7(2), 109-121 (1997).
50. Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J. Dev. Behav. Pediatr. 24(2), 104-108 (2003).
51. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 12(3), 243-248 (2002).
52. King BH, Hollander E, Sikich L, et al.; STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch. Gen. Psychiatry. 66(6), 583-590 (2009).
53. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry 44(4), 343-348 (2005).
54. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30(3), 582-589 (2005).
55. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am. J. Psychiatry 169(3), 292-299 (2012).
56. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J. Clin. Psychopharmacol. 18(1), 62-66 (1998).
57. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen. Psychiatry 53(11), 1001-1008 (1996).
58. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J. Autism Dev. Disord. 35(3), 377-385 (2005).
59. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J. Autism Dev. Disord. 30(5), 427-435 (2000).
60. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J. Autism Dev. Disord. 33(1), 77-85 (2003).
61. Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior. J. Am. Acad. Child Adolesc. Psychiatry 33(6), 909-910 (1994).
62. Posey DI, Litwiller M, Koburn A, McDougle CJ. Paroxetine in autism. J. Am. Acad. Child Adolesc. Psychiatry 38(2), 111-112 (1999).
63. Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am. J. Ment. Retard. 102(5), 427-437 (1998).
64. Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. J. Child Adolesc. Psychopharmacol. 19(2), 203-206 (2009).
65. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 11(3), 267-277 (2001).
66. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/ hyperactivity disorders (ADHD)-like symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(2), 312-315 (2006).
67. Marshall BL, Napolitano DA, Mcadam DB, Dunleavy IJ, Tessing JL, Varrell J. Venlafaxine and increased aggression in a female with autism. J. Am. Acad. Child Adolesc. Psychiatry 42(4), 383-384 (2003).
68. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J. Child Neurol. 15(2), 132-135 (2000).
69. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35(4), 990-998 (2010).
70. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J. Clin. Psychiatry 62(7), 530-534 (2001).
71. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 15(4), 682-692 (2005).
72. Epperson CN, McDougle CJ, Anand A, et al. Lithium augmentation of fluvoxamine in autistic disorder: a case report. J. Child Adolesc. Psychopharmacol. 4(3), 201-207 (1994).
73. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 26(6), 932-935 (1987).
74. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord. 31(2), 175-181 (2001).
75. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25(6), 284-289 (1994).
76. De Kleine R A, Hendriks GJ, Kusters WJ, Broekman TG, Van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry 71(11), 962-968 (2012).
77. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 63(3), 298-304 (2006).
78. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry 165(3), 335-341; quiz 409 (2008).
79. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of d-cycloserine in subjects with autistic disorder. Am. J. Psychiatry 161(11), 2115-2117 (2004).
80. Erickson CA, Posey DJ, Stigler K A, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 191(1), 141-147 (2007).
81. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 16(5), 517-524 (2006).
82. McDougle CJ, Posey D. Genetics of childhood disorders: XLIV. autism, part 3: psychopharmacology of autism. J. Am. Acad. Child Adolesc. Psychiatry 41(11), 1380-1383 (2002).
83. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J. Child Adolesc. Psychopharmacol. 14(2), 207-218 (2004).
84. Sturm H, Fernell E, Gillberg C. Autism spectrum disorders in children with normal intellectual levels: associated impairments and subgroups. Dev. Med. Child Neurol. 46(7), 444-447 (2004).
85. Goldstein S, Schwebach AJ. The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: results of a retrospective chart review. J. Autism Dev. Disord. 34(3), 329-339 (2004).
86. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J. Autism Dev. Disord. 25(3), 283-294 (1995).
87. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. 30(3), 245-255 (2000).
88. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J. Clin. Psychopharmacol. 12(5), 322-327 (1992).
89. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J. Clin. Psychiatry 53(3), 77-82 (1992).
90. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol. Psychiatry 50(8), 609-613 (2001).
91. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol. Psychiatry 43(4), 270-277 (1998).
92. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 67(7), 692-694 (2010).
93. Krueger DD, Bear MF. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Ann. Rev. Med. 62, 411-429 (2011).
94. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(1), 32-36 (2010).
95. Autism Speaks. Autism Speaks announces results reported for the study of fluoxetine in autism (SOFIA). First industry-sponsored trial for the Autism Clinical Trials Network (ACTN) (2009). www.autismspeaks.org/about-us/press- releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia (Accessed 4 February 2013)
96. ClinicalTrials.gov. A trial of memantine versus placebo in children with autism (2013). www.clinicaltrials.gov/ct2/show/NCT01372 449?term= A+trial+of+memantine+versus+pla cebo+in+children+with+autism.&rank=1 (Accessed 2 March 2013)
97. ClinicalTrials.gov. An open-label safety study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (2013). www.clinicaltrials.gov/ct2/show/ NCT01592786?term=An+open-label+safety +study+of+memantine+in+pediatric+patient s+with+autism%2C+Asperger%E2%80%99 s+Disorder%2C+or+pervasive+development al+disorder+not+otherwise+specified&ra nk=1 (Accessed 2 March 2013)